Abstract Details

Title Objective Measurement of Cognitive Impairment in Multiple Sclerosis Patients Using Novel Computerized Testing

Topic Multiple Sclerosis

Presentation(s) P10 - Poster Session 10 (5:30 PM-6:30 PM)

Poster/Presentation
Number 9-021

Objective At the completion of this presentation, participants should be able to assess the reliability of Cognivue^® as a cognitive assessment tool in multiple sclerosis (MS).

Background Cognivue^® is an FDA-cleared computerized testing tool rooted in adaptive psychophysics and designed to assess early signs of cognitive impairment (CI). CI has a substantial impact on productivity and quality of life in patients with MS, but testing has been limited. A brief, easy-to-administer neuropsychological test could increase the frequency of routine assessment of cognitive impairment among patients with MS, leading to a positive impact on MS management.

Design/Methods The study was conducted at the University of Massachusetts Medical School between June 2016 and May 2017, and enrolled consecutive patients who consented to testing. Study participants completed the Expanded Disability Status Scale (EDSS), symbol digit modality test (SDMT), 9 hole peg test, timed 25-foot walk, and 10-minute Cognivue^® testing (basic motor & visual ability, perceptual processing, and memory processing). Statistical analyses using a one-way ANOVA were performed to determine differences between neuropsychological testing methods.

Results Thirty-six patients (mean age 48.6 y [range 20-74], 78% female [n=28/36]), completed the various tests. Based on Cognivue^® scores, 50% of patients were categorized as having normal cognitive function (mean 84.7; EDSS 2.64), 33.3% as having low to moderate CI (mean 66.0; EDSS 3.38), and 16.7% as having severe CI (mean 39.2; EDSS 5.17). Overall Cognivue^® scores demonstrated statistically significant correlations with EDSS (Pearson correlation coefficient -0.54), SDMT (0.67), and timed 25-foot walk (-0.56). No relationship was seen between patient age and Cognivue^® scores. All key cognitive domains were equally affected.

Conclusions Cognivue^® is beneficial in detecting early stages of multi-domain CI in MS patients providing a potential opportunity for early intervention strategies to improve patient outcomes.

Authors/Disclosures
Roberto Bomprezzi, MD, F�鶹��ýӳ�� (University of Massachusetts, Dept. of Neurology) PRESENTER	Dr. Bomprezzi has nothing to disclose.
	No disclosure on file
Kara M. Smith, MD, F�鶹��ýӳ�� (Boston Medical Center)	Dr. Smith has received personal compensation in the range of $0-$499 for serving as a Consultant for PureTech. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Altec Inc. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amneal Pharmaceuticals. Dr. Smith has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Massachusetts Board of Medicine. The institution of Dr. Smith has received research support from NIH. Dr. Smith has received personal compensation in the range of $0-$499 for serving as a single time expert panel discussion contributor with Acadia.
Reina Benabou, MD, PhD	No disclosure on file

�鶹��ýӳ��

�鶹��ýӳ��